PROJECT 2 - ECONOMIC BURDEN OF CANCER: IMPACT OF AGE, STAGE, COMORBIDITIES AND

项目 2 - 癌症的经济负担：年龄、阶段、合并症和

基本信息

批准号：
7303415
负责人：
MARK CHRISTOPHER HORNBROOK
金额：
$ 14.07万
依托单位：
KAISER FOUNDATION HEALTH PLAN OF WASHINGTON
依托单位国家：
美国
项目类别：
财政年份：
2007
资助国家：
美国
起止时间：
2007-03-01 至 2012-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7303415
关键词：
Address Adopted Adoption Adult Adverse effects Age Antineoplastic Agents Appendix Aromatase Inhibitors Attention Breast Bronchi Cancer Intervention Cancer Patient Cancer Survivor Caring Chemopreventive Agent Childhood Clinical Clinical Oncology Clinical Trials Colon, Rectum Colony-Stimulating Factors Communities Comorbidity Cost Sharing Data Data Sources Databases Decision Making Diagnosis Diffusion Drug Prescriptions Economic Burden Economics Eligibility Determination Gender Glossary Guidelines Health Care Costs Health Expenditures Health Maintenance Organizations Health Planning Healthcare Incidence Injection of therapeutic agent Inpatients Knowledge Legal Lung Maintenance Malignant Neoplasms Marketing Measurement Measures Medical Medical Care Costs Medicare Medicine Modeling Modernization Monitor Nature Oncologist Outcome Outpatients Participant Patients Pattern Patterns of Care Peer Review Persons Pharmaceutical Cares Pharmaceutical Preparations Pharmaceutical Services Pharmacists Pharmacologic Substance Pharmacotherapy Pharmacy and Therapeutics Committee Pharmacy facility Phase Play Policies Population Process Prostate Publishing Race Rate Rectal Cancer Relative (related person)Research Resources Review Literature Role Screening procedure Severities Staging Standards of Weights and Measures Surveys Tamoxifen Testing Therapeutic Time Translating United States Food and Drug Administration Variant base beneficiary cancer care cancer prevention cancer site cancer therapy chemotherapy cost cost effectiveness end of life end of life care experience novel pharmacy benefit programs research study social

项目摘要

Total medical care costs of cancers are estimated to be about 5% of national health care expenditures and 10% of Medicare outlays. Accurate measures of medical care costs are important when evaluating cancer interventions, cancer clinical trials, social experiments related to cancer patients, and programs and policies related to cancer prevention, screening, and treatment. This research will take advantage of the HMO Research Network's (HMORN) unique resources to address vital questions related to the manner in which usual care drugs and novel pharmacy-based cancer therapies impact cancer-related health care costs. Specifically we propose the following aims: AIM 1 - We will conduct a survey of leaders of Pharmacy and Therapeutics (P&T) committees, clinical oncology pharmacists, and chief oncologists at the 15 HMORN plans to better understand how policies and guidelines related to the use of new cancer therapies, factors related to the decision-making process for why and when therapies were adopted and/or controlled (e.g., costs, legal claims, scientific evidence, visibility, community standards, patient demands), proportion of patients who refuse cancer therapies due to costs, and issues related to automated data on injection/infused cancer therapies. AIM 2 - Using data from four plans within the HMORN for 2000-2007, we will estimate the effects of variations in benefit coverage and cost sharing (patient out-of-pocket costs) on the total health care costs of cancer overall and for each specific component of care, with a specific emphasis on pharmaceutical costs for all cancer patients and the following specific cancer sites: breast, prostate, lung/bronchus, and colon/rectum cancers. Estimates will be made for all treatment phases (diagnosis/treatment, monitoring, and end-of-life care) for all persons with unique estimates for persons aged 65 and older. Aim 3 - Using HMORN data for 2000-2007 and Medicare Part D claims data for 2006-2007, we will estimate the rates of diffusion of targeted chemotherapy agents, colony-stimulating factors (CSFs), chemopreventive agents, new chemotherapy agents, and novel therapies developed during the past decade among Medicare HMO and FFS enrollees. We will describe the relative costs of these therapies to patients, health plans, and Medicare. AIM 4 - Using HMORN data for 2000-2007, and SEER-Medicare data for 2006-2007, we will model the effects of the increased drug coverage provided by the Medicare Prescription Drug Improvement and Modernization Act of 2003 (Part D) on estimates of cancer-related pharmaceutical services and overall medical care use and costs by cancer site, phase of treatment, and demographic strata (age/race/gender) for Medicare FFS and HMO beneficiaries.

据估计，癌症的总医疗费用约占国家卫生保健支出的5％和医疗保险支出的10％。评估癌症时，准确的医疗费用衡量很重要干预措施，癌症临床试验，与癌症患者有关的社会实验以及计划和政策与预防癌症，筛查和治疗有关。这项研究将利用HMO 研究网络（HMORN）的独特资源，以解决与方式相关的重要问题通常的护理药物和新型药房癌症疗法会影响与癌症相关的医疗保健费用。具体而言，我们提出以下目的：目标1-我们将对临床的药房和治疗学（P＆T）委员会进行调查 15 Hmorn计划的肿瘤学药师和首席肿瘤学家计划更好地了解政策和政策与使用新癌症疗法有关的指南，与决策过程有关的因素当采用疗法和/或受控治疗时（例如，成本，法律索赔，科学证据，可见性，社区标准，患者需求），因费用而拒绝癌症治疗的患者比例以及与注射/注射癌症疗法的自动数据有关的问题。 AIM 2-使用2000 - 2007年HMorn中四个计划的数据，我们将估计福利覆盖范围和成本分担的变化（患者自付费用）癌症总体和护理的每个特定组成部分，并特别强调药品成本所有癌症患者和以下特定癌症部位：乳腺癌，前列腺，肺/支气管和结肠/直肠癌症。将对所有治疗阶段（诊断/治疗，监测和寿命终止）进行估计护理）所有对65岁及以上人群的独特估计的人。 AIM 3-使用2000-2007的HMORN数据和2006-2007的Medicare D部分索赔数据，我们将估计靶向化疗剂的扩散率，刺激因子（CSF），化学预防剂的扩散率在过去的十年中 HMO和FFS参与者。我们将描述这些疗法对患者，健康计划和 Medicare。 AIM 4-使用2000-2007的HMORN数据，以及2006-2007的Seer-Medicare数据，我们将建模 Medicare处方药改善提供的药物覆盖范围增加的影响 2003年的现代化法案（D部分）关于癌症相关药物服务的估计和整体癌症现场的医疗保健使用和成本，治疗阶段和人口统计层（年龄/种族/性别） Medicare FFS和HMO受益人。